CIGB 55

Drug Profile

CIGB 55

Alternative Names: Anti-IL-15 peptide - CIGB

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class
  • Mechanism of Action Immunosuppressants; Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 25 Feb 2016 CIGB has patent protection for CIGB 55 in USA, the EU, Japan, Australia, Canada, China, Russia, Mexico and South Africa prior to February 2016
  • 01 Dec 2014 CIBG 55 is available for licensing as of 01 Dec 2014.
  • 31 Dec 2013 Preclinical trials in Autoimmune disorders in Cuba (unspecified route) (CIGB presentation,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top